A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at . A replay of the webcast will be archived on the ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

Discover the Vanguard Mega Cap Value ETF (MGV) - a value-focused investment option offering low volatility and attractive ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

These high-quality investment funds offer a combination of exposure to today's hottest growth trends and diversification ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.

All of this makes Intuitive a player that could offer you both security and growth this year and beyond. CRISPR ...

Here are my three favorite Vanguard ETFs to buy and hold for decades. Warren Buffett doesn't give a seal of approval to ETFs ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

The CRSP U.S. Mid Cap Index comprises stocks that fall within about the 80th percentile of U.S. stock market capitalization.